Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem

Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem

Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-media...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2019-12, Vol.25 (24), p.7272-7274
Hauptverfasser: Larocca, Cecilia, Kupper, Thomas S, LeBoeuf, Nicole R
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized
Humans
Mycosis Fungoides
Sezary Syndrome
Skin Neoplasms
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells. .
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-19-2742